Search results
Showing 631 to 645 of 1975 results for nice guidelines
This guideline covers supporting the social and emotional wellbeing of vulnerable children under 5 through home visiting, childcare and early education. It aims to optimise care for young children who need extra support because they have or are at risk of social or emotional problems.
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.
How to register as a stakeholder with NICE.
How to register as a stakeholder with NICE.
Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)
Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis
Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.
How you can use our recommendations, tools and resources: cardiovascular disease
How to use NICE guidance to reduce health inequalities in people experiencing cardiovascular disease (CVD).
In virtual wards, patients remain at home to receive hospital-level care. Our guidance can help you determine if patients are suitable for admission to the virtual wards system.
This indicator covers patient experiences of dental services. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.
Myocardial infarction: medication for MI in preceding 12 months (IND125)
This indicator covers the percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), dual antiplatelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM79
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.